RxSight
RXST

$52.95

1.03%

Market Cap: $2.1B

About: RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Employees: 374

Healthcare Ophthalmic Goods

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

466% more call options, than puts

Call options by funds: $4.25M | Put options by funds: $752K

155% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 20

75% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 7 (+3) [Q2]

21% more capital invested

Capital invested by funds: $1.64B [Q1] → $1.98B (+$345M) [Q2]

16% more funds holding

Funds holding: 195 [Q1] → 226 (+31) [Q2]

4% less repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 78

1.26% less ownership

Funds ownership: 85.74% [Q1] → 84.48% (-1.26%) [Q2]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$54

2%

upside

Avg. target

$64

21%

upside

High target

$73

38%

upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

Needham David Saxon 37% 1-year accuracy 24 / 65 met price target	25%upside $66	Buy Maintained	20 Aug 2024
Wells Fargo Larry Biegelsen 68% 1-year accuracy 25 / 37 met price target	2%upside $54	Overweight Maintained	6 Aug 2024
Oppenheimer Steven Lichtman 72% 1-year accuracy 13 / 18 met price target	23%upside $65	Outperform Maintained	6 Aug 2024
Stifel Thomas Stephan 63% 1-year accuracy 12 / 19 met price target	23%upside $65	Buy Maintained	6 Aug 2024
Needham David Saxon 37% 1-year accuracy 24 / 65 met price target	2%upside $54	Buy Maintained	6 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about RXST published over the past 30 days

RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences

ALISO VIEJO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced its plans to participate in two upcoming healthcare conferences in September.

RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences

Investing In The Future Of Cataract Surgery: The RxSight Advantage

RxSight, Inc. is transforming cataract surgery with the Light Adjustable Lens system, offering postoperative customization for superior vision outcomes. The global cataract devices market is rapidly expanding, with RxSight well-positioned to capitalize on the growing demand for premium IOLs. Impressive financial performance in Q2 2024, with significant revenue growth, gross profit margin improvement, and raised full-year revenue guidance.

Investing In The Future Of Cataract Surgery: The RxSight Advantage

Zacks Investment Research

Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect?

The mean of analysts' price targets for RxSight (RXST) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect?

RxSight, Inc. (RXST) Q2 2024 Earnings Call Transcript

RxSight, Inc. (NASDAQ:RXST ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Ron Kurtz - President, Chief Executive Officer Shelley Thunen - Assistant Secretary, Chief Financial Officer Oliver Moravcevic - Vice President, Investor Relations Conference Call Participants Ryan Zimmerman - BTIG Robbie Marcus - J.P. Morgan Steven Lichtman - Oppenheimer & Co. Inc. David Saxon - Needham & Company Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Tom Stephan - Stifel Operator Good day and thank you for standing by.

RxSight, Inc. (RXST) Q2 2024 Earnings Call Transcript

Zacks Investment Research

RxSight, Inc. (RXST) Reports Break-Even Earnings for Q2

RxSight, Inc. (RXST) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.40 per share a year ago.

RxSight, Inc. (RXST) Reports Break-Even Earnings for Q2

RxSight, Inc. Reports Second Quarter 2024 Financial Results

ALISO VIEJO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2024.

RxSight, Inc. Reports Second Quarter 2024 Financial Results

The 3 Best Med Tech Stocks to Buy Now

According to the Advanced Medical Technology Association, med tech is defined as “companies that develop, manufacture, and distribute the technologies, devices, equipment, diagnostic tests, and health information systems.” The organization reports that these firms favorably change health care with “earlier disease detection, less-invasive procedures, and more effective treatments.

The 3 Best Med Tech Stocks to Buy Now

Zacks Investment Research

Down -26.04% in 4 Weeks, Here's Why RxSight (RXST) Looks Ripe for a Turnaround

RxSight (RXST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -26.04% in 4 Weeks, Here's Why RxSight (RXST) Looks Ripe for a Turnaround

RxSight, Inc. to Report Second Quarter Financial Results on August 5, 2024

ALISO VIEJO, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the second quarter of 2024 after the market close on Monday, August 5, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

RxSight, Inc. to Report Second Quarter Financial Results on August 5, 2024

Zacks Investment Research

RxSight (RXST) Loses -16.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for RxSight (RXST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

RxSight (RXST) Loses -16.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

See News Rankings